NCT00987376

CompletedPhase 1

Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk...

Mayo Clinic Source

Mayo Clinic

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

8-03

Secondary identifiers

CA91956-02

Study Type

interventional

Actual enrollment (reported)

8

Locations

1 country

Sites

1

Timeline

Study Start

November 2003

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

September 2009

Actual (reported)

Study Completion

September 2009

Actual (reported)

Brief Summary

Prostate cancer imaging using traditional anatomic modalities including CT, MR, and ultrasound is limited. Improvement in current imaging modalities or development of new ones should be a priority in prostate cancer research. Optimal treatment varies considerably for patients with different staging characterizations and new imaging methods that more accurately stage patients could lead to more appropriate treatment. The objective of this study is to obtain preliminary, comparative data on new, promising imaging methods for prostate cancer. PET/CT imaging using 11C-choline,11C-acetate, and Y86 or 18F-Adenosylcobalamin and MRI spectroscopy (MRS) of prostate cancer will be compared. Direct comparison of these imaging methods has never been done and Mayo Clinic and Johns Hopkins are uniquely able to conduct such a trial as an inter-SPORE collaboration.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 8 participants
Study completion date: September 2009
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
November 2003
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
December 20, 2007
Actual (reported)
Primary Completion
September 2009
Actual (reported)
Study Completion
September 2009
Actual (reported)
First Posted
September 30, 2009
Actual (reported)

Last Updated: January 13, 2016
Status Verified: January 2016
Last Update Submitted: January 12, 2016

Conditions

Prostate Cancer

Outcome Measures

Primary Outcomes (1)

Test accuracy
2 years

Secondary Outcomes (1)

Test comparative accuracy of PET and MRI
2years

Study Arms (1)

1

EXPERIMENTAL

Prostate cancer patients

Device: Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy

Interventions

Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI SpectroscopyDevice

C11 Choline, C11 Acetate PET and MRI

1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexmale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Males 18 years of age or older
Patients who have completed staging CT and/or bone scan as part of their routine workup

Sponsors & Collaborators

Mayo Clinic
Otherlead
National Cancer Institute (NCI)
NIHcollaborator

Study Sites (1)

Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Enrollment

8 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: DIAGNOSTIC
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Val J. Lowe, MD

Study Record Dates

First Submitted

December 20, 2007

First Posted

September 30, 2009

Study Start

November 2003

Date type not reported

This date has not been verified as actual or estimated.

NCT00030290

Ultrasound in Treating Patients With Prostate Cancer Confined to the Prostate

Phase 1Completed

NCT00790595

Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy

Phase 1Completed

NCT00705835

Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

Phase 1Completed

NCT00215709

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

Phase 1Completed

NCT00052000

A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer

Phase 1Completed

NCT00328614

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Phase 1Completed

Patients with bulky metastatic prostate cancer who have 5 or more lesions suspicious for distant metastases as determined by routine CT and/or bone scans that are untreated by radiation

You may not qualify if:

Patients who are less than 6 weeks post operative for Greenfield filter placement
Patients with metallic surgical implants including pacemaker implants, cochlear implants, dentures held in place by magnets imbedded in the gums and aneurysm clips except those inserted at Mayo and only those inserted after October of 1994 and /or metal fragments in the body including metal fragments in the eyes

Contact the study team to confirm eligibility.

Primary Completion

September 2009

Actual (reported)

Study Completion

September 2009

Actual (reported)

Last Updated

January 13, 2016

Record last verified: 2016-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00987376
Data provider: ClinicalTrials.gov
Source updated: 2016-01-13
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:21:08 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

Primary Completion

Study Completion

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations